
Novo Nordisk plans to expand its selection of doses in which the firm may sell the diabetes drug Ozempic. Recently, this resulted in an application to the European Medicines Agency for extending the current label, according to the company's press announcement.
Currently, Ozempic is approved for treating type 2 diabetes in doses of 0.5 mg and 1.0 mg, but Novo Nordisk also wishes to apply for the approval of a 2.0 mg dose.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app